{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:16:34Z","timestamp":1793132194020,"version":"4.5.0"},"reference-count":92,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1\/2 resulting in first approved JAK1\/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF). Although JAK1\/2 inhibitor therapy is effective in decreasing the burden of symptoms associated with splenomegaly and MF-related constitutional symptoms, it is neither curative nor effective in reducing the risk of leukemic transformation. Presently, allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for MF. A significant risk of regimen-related toxicities, graft failure, and GVHD are major barriers to the success of HCT in MF. Because of significant HCT-associated morbidity and mortality, divergent opinions regarding its appropriate role in this clinical situation have emerged. In this review, the risk-benefit ratios of modern drug therapy compared with HCT in MF patients are analyzed. A risk-adapted approach individualized to each patient's biologic characteristics and comorbidities is described, which is currently warranted in determining optimal treatment strategies for patients with MF. Inclusion of JAK1\/2 inhibitor therapy in future transplant conditioning regimens may provide an opportunity to overcome some of these barriers, resulting in greater success with HCT for MF patients.<\/jats:p>","DOI":"10.1182\/blood-2012-05-399048","type":"journal-article","created":{"date-parts":[[2012,6,14]],"date-time":"2012-06-14T20:20:06Z","timestamp":1339705206000},"page":"1367-1379","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":95,"title":["Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors"],"prefix":"10.1182","volume":"120","author":[{"given":"Vikas","family":"Gupta","sequence":"first","affiliation":[{"name":"Princess Margaret Hospital, University of Toronto, Toronto, ON;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, WI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Mount Sinai School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"17","key":"2019111811250865600_B1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia.","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111811250865600_B2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","article-title":"Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.","volume":"61","author":"Mesa","year":"1999","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111811250865600_B3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the Mayo Clinic experience.","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"13","key":"2019111811250865600_B4","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111811250865600_B5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111811250865600_B6","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"26","key":"2019111811250865600_B7","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1182\/blood-2011-04-349142","article-title":"Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis.","volume":"117","author":"Deeg","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2019111811250865600_B8","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis.","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111811250865600_B9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.bmt.1704075","article-title":"Stem cell transplantation for myelofibrosis: a report from two Canadian centers.","volume":"32","author":"Daly","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2019111811250865600_B10","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis.","volume":"102","author":"Deeg","year":"2003","journal-title":"Blood"},{"issue":"9","key":"2019111811250865600_B11","first-page":"2831","article-title":"Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study.","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"issue":"7","key":"2019111811250865600_B12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2010.32.5001","article-title":"Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?","volume":"29","author":"Horan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111811250865600_B13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08582.x","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.","volume":"153","author":"Samuelson","year":"2011","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111811250865600_B14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111811250865600_B15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"2019111811250865600_B16","first-page":"793","article-title":"Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib (INCB018424) to those of a historical control group: survival advantage of ruxolitinib therapy [abstract].","volume":"118","author":"Verstovsek","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"15","key":"2019111811250865600_B17","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMc1109555","article-title":"Long-term outcome of treatment with ruxolitinib in myelofibrosis.","volume":"365","author":"Tefferi","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111811250865600_B18","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","article-title":"JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths.","volume":"119","author":"Tefferi","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111811250865600_B19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"issue":"9","key":"2019111811250865600_B20","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.leukres.2010.05.008","article-title":"Therapeutic options for patients with myelofibrosis in blast phase.","volume":"34","author":"Mascarenhas","year":"2010","journal-title":"Leuk Res"},{"issue":"3","key":"2019111811250865600_B21","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2019111811250865600_B22","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"15","key":"2019111811250865600_B23","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.","volume":"116","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111811250865600_B24","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2141.2010.08275.x","article-title":"Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence.","volume":"150","author":"Passamonti","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111811250865600_B25","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/leu.2011.374","article-title":"Leukemia risk models in primary myelofibrosis: an International Working Group study.","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"2019111811250865600_B26","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.21868","article-title":"Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.","volume":"106","author":"Dingli","year":"2006","journal-title":"Cancer"},{"issue":"7","key":"2019111811250865600_B27","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2007-11-121434","article-title":"A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.","volume":"111","author":"Passamonti","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111811250865600_B28","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood.V72.3.855.855","article-title":"Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases.","volume":"72","author":"Demory","year":"1988","journal-title":"Blood"},{"issue":"1","key":"2019111811250865600_B29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2141.1997.1722990.x","article-title":"Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases.","volume":"98","author":"Reilly","year":"1997","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111811250865600_B30","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1182\/blood-2010-11-320002","article-title":"Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival.","volume":"117","author":"Vaidya","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111811250865600_B31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1600-0609.2009.01298.x","article-title":"The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.","volume":"83","author":"Hidaka","year":"2009","journal-title":"Eur J Haematol"},{"issue":"1","key":"2019111811250865600_B32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","article-title":"Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.","volume":"25","author":"Caramazza","year":"2011","journal-title":"Leukemia"},{"issue":"18","key":"2019111811250865600_B33","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2008-09-178541","article-title":"The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"issue":"9464","key":"2019111811250865600_B34","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"2019111811250865600_B35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"17","key":"2019111811250865600_B36","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"7037","key":"2019111811250865600_B37","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"5","key":"2019111811250865600_B38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111811250865600_B39","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111811250865600_B40","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"5","key":"2019111811250865600_B41","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.","volume":"107","author":"Campbell","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111811250865600_B42","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111811250865600_B43","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"12","key":"2019111811250865600_B44","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111811250865600_B45","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/leu.2011.161","article-title":"Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.","volume":"25","author":"Pardanani","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"2019111811250865600_B46","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res"},{"issue":"19","key":"2019111811250865600_B47","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms reveals recurrent SRSF2 mutations which are associated with adverse outcome.","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111811250865600_B48","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","article-title":"Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.","volume":"89","author":"Mart\u00ednez-Trillos","year":"2010","journal-title":"Ann Hematol"},{"issue":"2","key":"2019111811250865600_B49","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"key":"2019111811250865600_B50","first-page":"3849","article-title":"An expanded multicenter phase I\/II study of CYT387, a JAK- 1\/2 inhibitor for the treatment of myelofibrosis [abstract].","volume":"118","author":"Pardanani","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"7","key":"2019111811250865600_B51","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111811250865600_B52","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111811250865600_B53","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","article-title":"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.","volume":"115","author":"Tyner","year":"2010","journal-title":"Blood"},{"issue":"26","key":"2019111811250865600_B54","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"key":"2019111811250865600_B55","first-page":"1750","article-title":"Results of phase II clinical trial MPD-RC 101: allogeneic hematopoietic stem cell transplantation conditioned with fludarabine\/melphalan in patients with myelofibrosis [abstract].","volume":"118","author":"Rondelli","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"3","key":"2019111811250865600_B56","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis.","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111811250865600_B57","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","article-title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111811250865600_B58","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111811250865600_B59","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/sj.bmt.1702568","article-title":"Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect.","volume":"26","author":"Cervantes","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111811250865600_B60","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood.V99.6.2255","article-title":"Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.","volume":"99","author":"Devine","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111811250865600_B61","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1046\/j.1365-2141.2000.01826.x","article-title":"Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a \u2018graft vs myelofibrosis\u2019 effect.","volume":"108","author":"Byrne","year":"2000","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111811250865600_B62","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions.","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111811250865600_B63","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type.","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2019111811250865600_B64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/bmt.2009.10","article-title":"A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis.","volume":"44","author":"Gupta","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111811250865600_B65","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3324\/haematol.12828","article-title":"Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).","volume":"93","author":"Patriarca","year":"2008","journal-title":"Haematologica"},{"issue":"10","key":"2019111811250865600_B66","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2004-11-4299","article-title":"Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia.","volume":"105","author":"Rondelli","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2019111811250865600_B67","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/bmt.2011.91","article-title":"The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries.","volume":"47","author":"Abelsson","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"2019111811250865600_B68","article-title":"Risk models predicting survival after reduced-intensity transplantation for myelofibrosis [published online ahead of print January 27, 2012].","author":"Alchalby","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111811250865600_B69","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.bbmt.2011.05.003","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk.","volume":"18","author":"Nivison-Smith","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111811250865600_B70","article-title":"DIPSS scores, pre-transplant therapy and chronic GVHD determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis [published online ahead of print April 4, 2012].","author":"Ditschkowski","journal-title":"Haematologica"},{"issue":"18","key":"2019111811250865600_B71","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","article-title":"Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.","volume":"116","author":"Alchalby","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111811250865600_B72","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.bbmt.2006.07.010","article-title":"No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.","volume":"12","author":"Ditschkowski","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111811250865600_B73","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/bmt.2011.17","article-title":"Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT.","volume":"47","author":"Alchalby","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111811250865600_B74","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2009-11-252601","article-title":"Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis.","volume":"116","author":"Takagi","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111811250865600_B75","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood.V97.7.2180","article-title":"Splenectomy and hemopoietic stem cell transplantation for myelofibrosis.","volume":"97","author":"Li","year":"2001","journal-title":"Blood"},{"issue":"11","key":"2019111811250865600_B76","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bmt.2010.14","article-title":"The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.","volume":"45","author":"Stewart","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111811250865600_B77","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2141.2010.08276.x","article-title":"Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis.","volume":"150","author":"Robin","year":"2010","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111811250865600_B78","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1182\/blood-2008-11-190975","article-title":"JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.","volume":"113","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"key":"2019111811250865600_B79","article-title":"Incidence, risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation [published online ahead of print April 21, 2012].","author":"Wong","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2019111811250865600_B80","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1084\/jem.194.7.941","article-title":"Self-renewal of multipotent long-term repopulating hematopoietic stem cells is negatively regulated by Fas and tumor necrosis factor receptor activation.","volume":"194","author":"Bryder","year":"2001","journal-title":"J Exp Med"},{"issue":"6","key":"2019111811250865600_B81","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood.V98.6.1782","article-title":"Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells.","volume":"98","author":"Dybedal","year":"2001","journal-title":"Blood"},{"issue":"24","key":"2019111811250865600_B82","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111811250865600_B83","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9674","key":"2019111811250865600_B84","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease.","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"2019111811250865600_B85","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111811250865600_B86","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"7","key":"2019111811250865600_B87","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/leu.2011.82","article-title":"DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"2019111811250865600_B88","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"issue":"19","key":"2019111811250865600_B89","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis.","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111811250865600_B90","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2011-07-367243","article-title":"Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms.","volume":"119","author":"Score","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111811250865600_B91","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ajh.22257","article-title":"Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.","volume":"87","author":"Puda","year":"2012","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111811250865600_B92","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.2010.08417.x","article-title":"Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).","volume":"152","author":"Robin","year":"2011","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/7\/1367\/1499134\/zh803312001367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/7\/1367\/1499134\/zh803312001367.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T11:37:08Z","timestamp":1574077028000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/7\/1367\/30759\/Allogeneic-hematopoietic-cell-transplantation-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,16]]},"references-count":92,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,8,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-05-399048","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,16]]}}}